Axim Biotechnologies Debt To Equity vs. EBITDA
| AXIM Stock | USD 0 0 33.33% |
For Axim Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Axim Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Axim Biotechnologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Axim Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Axim Biotechnologies over time as well as its relative position and ranking within its peers.
Axim |
Axim Biotechnologies EBITDA vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Axim Biotechnologies's current stock value. Our valuation model uses many indicators to compare Axim Biotechnologies value to that of its competitors to determine the firm's financial worth. Axim Biotechnologies is number one stock in debt to equity category among its peers. It is rated second in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Axim Biotechnologies' earnings, one of the primary drivers of an investment's value.Axim EBITDA vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Axim Biotechnologies |
| = | 1.36 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Axim Biotechnologies |
| = | (13.42 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Axim EBITDA Comparison
Axim Biotechnologies is currently under evaluation in ebitda category among its peers.
Axim Biotechnologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Axim Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Axim Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Axim Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Axim Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
Axim Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Axim Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Axim Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Axim Biotechnologies' important profitability drivers and their relationship over time.
Use Axim Biotechnologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axim Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axim Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Axim Biotechnologies Pair Trading
Axim Biotechnologies Pair Trading Analysis
The ability to find closely correlated positions to Axim Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axim Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axim Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axim Biotechnologies to buy it.
The correlation of Axim Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axim Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axim Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axim Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Axim Biotechnologies position
In addition to having Axim Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Funds Thematic Idea Now
Money Funds
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Axim Pink Sheet
To fully project Axim Biotechnologies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Axim Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Axim Biotechnologies' income statement, its balance sheet, and the statement of cash flows.